SOURCE: Hathaway Corporation

December 04, 2007 06:31 ET

Hathaway's (HWYI) Subsidiary DDI Signs Prominent Physicians for Its Scientific Advisory Board

Past Chairman of American Diabetes Association Now Part of DDI Team

PALO ALTO, CA--(Marketwire - December 4, 2007) - Hathaway Corporation (PINKSHEETS: HWYI) announced that its subsidiary, Diabetes Detection, Inc. (DDI), has been successful in signing two of the leading physicians and clinical researchers of Neuropathy and Diabetes treatments, for its Scientific Advisory Board.

The highly respected physicians, who are authors of numerous research studies, papers and textbooks, have played significant leadership roles with various international Diabetes-related associations, including holding a past chairmanship of the American Diabetes Association. They have been responsible for, among other things, shaping the ADA's official position on Diabetic Neuropathies, and are strong and outspoken proponents for vibration testing for Neuropathy, the basis for DDI's technology.

The physicians are now actively helping with fine-tuning and enhancing the functionality of the DDI product, and with the structure and logistics of clinical trials.

"This is a major breakthrough," said Sadruddin Currimbhoy, DDI's CEO. "DDI's product has received tremendous validation with these signings. These individuals are the leaders in our field, and their involvement with DDI will be instrumental in proving the viability of our technology, and also with achieving widespread acceptance and adoption for the DDI product across the physician community."

DDI's first commercial offering is currently in its third generation prototype stage, and progressing rapidly towards marketability.

The Diabetes Market

The American Diabetes Association estimates that 20.8m, or 7% of the entire population of the United States has diabetes -- with this expected to continue to grow at a dramatic pace. The ADA estimates that direct medical and indirect expenditures attributable to diabetes in the US alone are $132 billion (2002).

About DDI

Diabetes Detection Inc.'s patent-pending Neuropathy testing technology converged with communications devices, facilitates the early detection of Diabetes, which is now in epidemic proportions, affecting 140m people worldwide, and predicted to grow to 300m in 25 years (Source: WHO).

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

Contact Information

  • Contact:

    FutureTechIR for Hathaway Corporation
    Investor Relations
    (817) 812-2105